Abstract
Structure- and ligand-based computational design strategies were used to understand the molecular requirements of furanyl derivatives 2-(furan-2-yl)-[1,2,4]triazolo[1,5-f]pyrimidin-5-amines (TfPAs), 2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine (TaPAs), and 2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amines (TTAs) as adenosine A2A receptor (A2AR) antagonists. First, we studied the structure–activity relationship of the selected compounds using hologram quantitative structure–activity relationship (HQSAR) methodology. The best model (training set included 67 compounds) included fragment parameters such as atoms (A), bonds (B), connections (C), and donors/acceptors groups (DA) and had a good q 2 value of 0.776 including size fragments of 7–10 and the hologram length of 199. It also predicted adequately the compounds contained in the test set (10 compounds). In addition, we studied the binding orientations of the higher and less active compounds using flexible molecular docking. We found orientations that are in agreement with previous reports.
Similar content being viewed by others
References
Alves CN, Barroso LP, Santos LS, Jardim IN (1998) Quantitative structure activity relationship of compounds which are anti-schistosomiasis active. J Braz Chem Soc 9:577–582
Alves CN, de Macedo LGM, Honorio KM, Camargo AJ, Santos LS, Jardim IN, Barata LES, da Silva ABF (2002) A structure–activity relationship (SAR) study of neolignan compounds with anti-schistosomiasis activity. J Braz Chem Soc 13:300–307
Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R (2011) Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther 132:280–299
Bacilieri M, Ciancetta A, Paoletta S, Federico S, Cosconati S, Cacciari B, Taliani S, Settimo FDa, Novellino E, Klotz KN, Spalluto G, Moro S (2013) Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists. J Chem Inf Model 53:1620–1637
Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R (2005) Integrated modeling program, applied chemical theory (IMPACT). J Comput Chem 26:1752–1780
Barnett-Cowan M, Dyde RT, Foxe SH, Moro E, Hutchison WD, Harris LR (2010) Multisensory determinants of orientation perception in Parkinson’s disease. Neuroscience 167:1138–1150
Bermejo PE (2007) Relación entre temblor esencial, enfermedad de Parkinson y demencia con cuerpos de Lewy. Rev Neurol 45:689–694
Brassat D, Durr A, Agid Y, Brice A (1999) Genetic aspect of Parkinson’s disease. La Revue de Médecine Interne 20:709–714
Bussell R, Eliezer D (2004) Effects of Parkinson’s disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry 43:4810–4818
Calgarotto AK, Miotto S, Honorio KM, da Silva ABF, Marangoni S, Silva JL, Comar M, Oliveira KMT, da Silva SL (2007) A multivariate study on flavonoid compounds scavenging the peroxynitrite free radical. J Mol Struct 808:25–33
Camargo AJ, Mercadante R, Honorio KM, Alves CN, da Silva ABF (2002) A structure–activity relationship (SAR) study of synthetic neolignans and related compounds with biological activity against Escherichia coli. J Mol Struct 583:105–116
Camargo AJ, Honorio KM, Mercadante R, Molfetta FA, Alves CN, da Silva ABF (2003) A study of neolignan compounds with biological activity against Paracoccidioides brasiliensis by using quantum chemical and chemometric methods. J Braz Chem Soc 14:809–814
Castilho MS, Postigo MP, de Paula CBV, Montanari CA, Oliva G, Andricopulo AD (2006) Two- and three-dimensional quantitative structure–activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorg Med Chem 14:516–527
Cramer RD III, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967
Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109–127
Devijver PA, Kittler J (1982) Pattern recognition—a statistical approach. Prentice-Hall, Engelwood Cliffs
Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, Tate CG, Weir M, Marshall FH (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19:1283–1293
Flower DR (1998) On the properties of bit string-based measures of chemical similarities. J Chem Inf Comput Sci 38:379–386
Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Mod 20:269–276
Heritage TW, Lowis DR (1999). Molecular hologram QSAR. In: Rational drug design: novel methodology and practical applications. Oxford University Press, New York
Hickey P, Stacy M (2012) Curr. Adenosine A2A antagonists in Parkinson’s disease: What’s next? Neurol Neurosci Rep 12:376–385
Honorio KM, Garratt RC, Andricopulo AD (2005) Hologram quantitative structure–activity relationships for a series of farnesoid X receptor activators. Bioorg Med Chem Lett 15:3119–3125
Honorio KM, Garratt RC, Polikarpov I, Andricopulo AD (2006) Hologram QSAR studies on farnesoid X receptor activators. Lett Drug Des Discov 3:261–267
Honorio KM, Salum LB, Garratt RC, Polikarpov I, Andricopulo AD (2008) Two- and three-dimensional quantitative structure–activity relationships studies on a series of liver X receptor ligands. Open Med Chem J 2:87–96
Jankovic JJ (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376
Keddie JR, Poucher SM, Shaw GR, Brooks R, Collis MG (1996) In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist. Eur J Pharmacol 301:107–113
Kim SK, Gao ZG, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S (2003) Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem 46:4847–4859
Kirchmair J, Wolber G, Laggner C, Langer T (2006) Comparative performance assessment of the conformational model generators omega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J Chem Inf Model 46:1848–1861
Knuth DE (1973) Sorting and searching. Addison-Wesley, Massachusetts
Kulisevsky J, Poyurovsky M (2012) Adenosine A2A-receptor antagonism and pathophysiology of Parkinson’s disease and drug-induced movement disorders. Eur Neurol 67:4–11
Lowis DR (1997) HQSAR: a new, highly predictive QSAR technique. Tripos Tech Notes 1(5):17
Matasi J, Caldwell JP, Zhang H, Fawzi A, Cohen-Williams ME, Varty GB, Deen B (2005) 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1. Bioorg Med Chem Lett 15:3670–3674
Michielan L, Bacilieri M, Schiesaro A, Bolcato C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Kaseda C, Moro S (2008) Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor. J Chem Inf Model 48:350–363
Moda TL, Montanari CA, Andricopulo AD (2007) Hologram QSAR model for the prediction of human oral bioavailability. Bioorg Med Chem 15:7738–7745
Morales-Bayuelo A, Vivas-Reyes R, Ayazo H (2010) Three-dimensional quantitative structure–activity relationship CoMSIA/CoMFA and LeapFrog studies on novel series of bicyclo [4.1.0] heptanes derivatives as melanin-concentrating hormone receptor R1 antagonists. Eur J Med Chem 45:4509–4522
Mota SGR, Barros TF, Castilho MS (2009) 2D QSAR studies on a series of bifonazole derivatives with antifungal activity. J Braz Chem Soc 20:451–459
Noyes K, Dick AW, Holloway RG (2006) Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health (ISPOR) 9:28–38
Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7:525–537
Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T (2008) Clinical correlates of depressive symptoms in familial Parkinson’s disease. Movement disorders: off. Mov Disord Off J Mov Disord Soc 23:2216–2223
Pinheiro AAC, Borges RS, Santos LS, Alves CN (2004) A QSAR study of 8.O.4-neolignans with antifungal activity. J Mol Struct 672:215–219
Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, Coll MG (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist. Br J Pharmacol 115:1096–1102
Poucher SM, Keddie JR, Brooks R, Shaw GR, McKillop D (1996) Pharmacodynamics of ZM 241385, a potent A2a adenosine receptor antagonist, after enteric administration in rat, cat and dog. J Pharm Pharmacol 48:601–606
Qin Z, Zhang L, Sun F, Fang F, Meng C, Tanner C, Chan P (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771
Ron K (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Proc Four Int Jt Conf Artif Intell (San Mateo, CA: Morgan Kaufmann) 2(12):1137–1143
Salum LB, Polikarpov I, Andricopulo AD (2007) Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. J Mol Graph Model 25:434–442
Salum LB, Dias LC, Andricopulo AD (2009) Structural and chemical basis for anticancer activity of a series of β-tubulin ligands: molecular modeling and 3D QSAR studies. J Braz Chem Soc 20:693–703
Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363:1783–1793
Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234
Schrödinger Suite 2014-2 Induced Fit Docking protocol; Glide version 6.3, Schrödinger, LLC, New York, NY, 2014; Prime version 3.6, Schrödinger, LLC, New York, NY, 2014 (n.d.)
Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553
Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, Heritage TW, Sheehan DM (1998) Evaluation of quantitative structure–activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 38:669–677
Valadares NF, Castilho MS, Polikarpov I, Garratt RC (2007) 2D QSAR studies on thyroid hormone receptor ligands. Bioorg Med Chem 15:4609–4617
Vargas LM (2007) Enfermedad de Parkinson y la Dopamina. BUN Synapsis 2:12–16
Venhuis BJ, Wikström HV, Rodenhuis N, Sundell S, Dijkstra D (2002) A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson’s disease. J Med Chem 45:2349–2351
Vu CB, Shields P, Peng B (2004) Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists. Bioorg Med Chem Lett 14:4835–4838
Weber KC, Honorio KM, Andricopulo AD, da Silva ABF (2008) Two-dimensional QSAR studies on arylpiperazines as high-affinity 5-HT1A receptor ligands. Med Chem 4:328–335
Wold S (1978) Cross-validatory estimation of the number of components in factor and principal component models. Technometrics 4:397–405
Xiang YH, Zhang ZY, Xiao AJ, Huo JX (2009) Recent studies of QSAR on inhibitors of estrogen receptor and human eosinophil phosphodiesterase. Curr Comput Aided Drug Des 5:200–214
Yan H, Pan XL, Tan NH, Fan JT, Zeng GZ, Han HJ (2009) 2D- and 3D-QSAR studies on 54 anti-tumor Rubiaceae-type cyclopeptides. Eur J Med Chem 44:3425–3432
Yao G, Haque S, Sha L, Kumaravel G, Wang J, Engber TM, Whalley E, Conlon PR, Chang H, Kiesman WF, Petter RC (2005) Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists. Bioorg Med Chem Lett 15:511–515
Young D (2001). Computational chemistry: a practical guide for applying techniques to real-world problems. Comput Chem. Appendix A. A.3.2 pg 342
Zanatta N, Borchhardt DM, Carpes AD, Marchia TM, Andricopulo AD, Salum LB, Schetinger MRC, Bonacorso HG, Martins MAR, Flores AEC (2008) Synthesis, screening for antiacetylcholinesterase activity and binding mode prediction of a new series of [3-(disubstituted-phosphate)-4,4,4-trifluoro-butyl]-carbamic acid ethyl esters. J Braz Chem Soc 19:1118–1124
Acknowledgments
A. M. B. thanks to the Universidad de Talca (CBSM) for the continuous support to this investigation, to the postdoctoral Project No. 3150035 (FONDECYT, CHILE). C. M. G. acknowledges support from doctoral fellowship CONICYT-PCHA/Folio 21120214. J. C. acknowledges funds of the Project FONDECYT 1130141.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Muñoz-Gutiérrez, C., Caballero, J. & Morales-Bayuelo, A. HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists. Med Chem Res 25, 1316–1328 (2016). https://doi.org/10.1007/s00044-016-1575-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-016-1575-1